Modulation of autophagy with hydroxychloroquine in patients with advanced non-small cell lung cancer (NSCLC): A phase Ib study.

被引：9
|
作者：
Malhotra, Jyoti
Jabbour, Salma
Orlick, Michelle
Riedlinger, Gregory
Joshi, Sonali
Guo, Jessie Yanxiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21138
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase Ib Trial of Afatinib and BI 836845 in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Park, Keunchil
    Lin, Chia-Chi
    Huang, Dennis Chin-Lun
    Shin, Heather Hye-Jung
    Bogenrieder, Thomas
    Tan, Daniel S. -W.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S554 - S555
  • [2] Phase Ib trial of afatinib and BI 836845 in advanced non-small cell lung cancer (NSCLC)
    Tan, D.
    Lin, C. -C.
    Huang, D. Chin-Lun
    Jung, H.
    Bogenrieder, T.
    Park, K.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [3] COMBINATION CHEMOTHERAPY AND AUTOPHAGY INHIBITION WITH HYDROXYCHLOROQUINE FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Aisner, Joseph
    Saraiya, Biren
    Surakanti, Sujani
    Mehnert, Janice
    White, Eileen
    Dipaola, Robert S.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1179 - S1179
  • [4] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea
    Cho, E. K.
    Kang, J. H.
    Han, J-Y.
    Lee, J. S.
    Kim, D-W.
    Kim, S-W.
    Min, Y. J.
    Lee, K. H.
    Kim, J-H.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Preliminary results from phase Ib study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Santoro, A.
    Garrido Lopez, P.
    Tan, D. S. W.
    Paz-Ares, L.
    Shepherd, F.
    Bearz, A.
    Barlesi, F.
    Vansteenkiste, J. F.
    Kim, T. M.
    Overbeck, T. R.
    Rybkin, I. I.
    Felip, E.
    Zhou, W.
    Santarpia, L.
    Eddy, S.
    Schaefer, E. S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] A PHASE IB WINDOW OF OPPORTUNITY CLINICAL STUDY WITH EVEROLIMUS IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
    Owonikoko, Taofeek K.
    Force, Seth
    Sica, Gabriel
    Bechara, Rabih
    Harvey, R. D.
    Sun, Shi-Yong
    Saba, Nabil
    Rogerio, Jaqueline
    Gal, Anthony
    Kono, Scott
    Miller, Daniel
    Ramalingam, Suresh
    Khuri, Fadlo R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S967 - S968
  • [7] Phase ib study of safety, tolerability and pharmacokinetics of simotinib in patients with advanced non-small cell lung cancer
    Hu, Xingsheng
    Han, Xiaohong
    Zhang, Li
    Ding, Yanhua
    Wang, Hanping
    Mu, Hua
    Sun, Yan
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC): Updated results of an ongoing study.
    Read, WL
    Toles, L
    Romvari, E
    Adkins, D
    McLeod, H
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 707S - 707S
  • [9] Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer (NSCLC).
    Miller, AA
    Case, D
    Atkins, J
    Giguere, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 649S - 649S
  • [10] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.
    Park, Keunchil
    Cho, Eun Kyung
    Kang, Jin Hyoung
    Han, Ji-Youn
    Lee, Jong Seok
    Kim, Dong-Wan
    Kim, Sang-We
    Cho, Byoung Chul
    Min, Young Joo
    Lee, Ki Hyeong
    Kim, Joo-Hang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
12345